JPWO2019200223A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019200223A5 JPWO2019200223A5 JP2020555862A JP2020555862A JPWO2019200223A5 JP WO2019200223 A5 JPWO2019200223 A5 JP WO2019200223A5 JP 2020555862 A JP2020555862 A JP 2020555862A JP 2020555862 A JP2020555862 A JP 2020555862A JP WO2019200223 A5 JPWO2019200223 A5 JP WO2019200223A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- cytokine
- patient
- cxcl9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004127 Cytokines Human genes 0.000 claims description 67
- 108090000695 Cytokines Proteins 0.000 claims description 67
- 206010028980 Neoplasm Diseases 0.000 claims description 66
- 201000011510 cancer Diseases 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 44
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 39
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 39
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 34
- 239000003112 inhibitor Substances 0.000 claims description 34
- 239000000090 biomarker Substances 0.000 claims description 30
- 210000002966 serum Anatomy 0.000 claims description 30
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 26
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 18
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 18
- 239000002955 immunomodulating agent Substances 0.000 claims description 18
- -1 IL-12p70 Proteins 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 16
- 102000003805 Chemokine CCL19 Human genes 0.000 claims description 14
- 108010082161 Chemokine CCL19 Proteins 0.000 claims description 14
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 14
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims description 13
- 102000000588 Interleukin-2 Human genes 0.000 claims description 13
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 12
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 9
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 9
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 claims description 8
- 102000004237 Decorin Human genes 0.000 claims description 8
- 108090000738 Decorin Proteins 0.000 claims description 8
- 206010018338 Glioma Diseases 0.000 claims description 8
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 230000002496 gastric effect Effects 0.000 claims description 8
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 208000021039 metastatic melanoma Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 102100034594 Angiopoietin-1 Human genes 0.000 claims description 7
- 108010048154 Angiopoietin-1 Proteins 0.000 claims description 7
- 108010081589 Becaplermin Proteins 0.000 claims description 7
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 7
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 7
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 7
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims description 7
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 6
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 6
- 102100023700 C-C motif chemokine 16 Human genes 0.000 claims description 6
- 102100036845 C-C motif chemokine 22 Human genes 0.000 claims description 6
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims description 6
- 102100036849 C-C motif chemokine 24 Human genes 0.000 claims description 6
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 6
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 6
- 108010083647 Chemokine CCL24 Proteins 0.000 claims description 6
- 108010055165 Chemokine CCL4 Proteins 0.000 claims description 6
- 102000001326 Chemokine CCL4 Human genes 0.000 claims description 6
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 claims description 6
- 108010024212 E-Selectin Proteins 0.000 claims description 6
- 102100023471 E-selectin Human genes 0.000 claims description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 6
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 claims description 6
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims description 6
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 claims description 6
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 6
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 claims description 6
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 6
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 6
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 6
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 6
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims description 6
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims description 6
- 102100029812 Protein S100-A12 Human genes 0.000 claims description 6
- 101710110949 Protein S100-A12 Proteins 0.000 claims description 6
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 6
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 claims description 6
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 6
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 6
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 6
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 6
- 229960003301 nivolumab Drugs 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 6
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 claims description 6
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims description 4
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 4
- 201000005185 adrenal cortical adenocarcinoma Diseases 0.000 claims description 4
- 229950002916 avelumab Drugs 0.000 claims description 4
- 210000000941 bile Anatomy 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000000564 macroglobulinemia Diseases 0.000 claims description 4
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 210000001635 urinary tract Anatomy 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims description 2
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 229950010773 pidilizumab Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229950007213 spartalizumab Drugs 0.000 claims description 2
- 229940066453 tecentriq Drugs 0.000 claims description 2
- 229940055760 yervoy Drugs 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862657370P | 2018-04-13 | 2018-04-13 | |
| US62/657,370 | 2018-04-13 | ||
| US201862734133P | 2018-09-20 | 2018-09-20 | |
| US62/734,133 | 2018-09-20 | ||
| US201862756496P | 2018-11-06 | 2018-11-06 | |
| US62/756,496 | 2018-11-06 | ||
| PCT/US2019/027169 WO2019200223A1 (en) | 2018-04-13 | 2019-04-12 | Cancer serum biomarkers and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521439A JP2021521439A (ja) | 2021-08-26 |
| JP2021521439A5 JP2021521439A5 (https=) | 2022-04-19 |
| JPWO2019200223A5 true JPWO2019200223A5 (https=) | 2022-04-19 |
Family
ID=68164571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555862A Pending JP2021521439A (ja) | 2018-04-13 | 2019-04-12 | がん血清バイオマーカーおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210025895A1 (https=) |
| EP (1) | EP3775877A4 (https=) |
| JP (1) | JP2021521439A (https=) |
| CN (1) | CN112005114A (https=) |
| CA (1) | CA3095331A1 (https=) |
| WO (1) | WO2019200223A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| PL3393468T3 (pl) | 2015-12-22 | 2023-01-23 | X4 Pharmaceuticals, Inc. | Metody leczenia niedoboru odporności |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| CN112771177A (zh) * | 2018-05-21 | 2021-05-07 | 纳米线科技公司 | 分子基因标签及其使用方法 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| WO2021263115A1 (en) * | 2020-06-26 | 2021-12-30 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment |
| AU2021409465A1 (en) | 2020-12-21 | 2023-08-03 | Freenome Holdings, Inc. | Markers for the early detection of colon cell proliferative disorders |
| US12523658B2 (en) * | 2021-08-27 | 2026-01-13 | The Board Of Regents Of The University Of Texas System | Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications |
| CA3233049A1 (en) * | 2021-09-20 | 2023-03-23 | Droplet Biosciences, Inc. | Lymphatic fluid for diagnostics |
| CN114859050B (zh) * | 2022-05-30 | 2026-02-17 | 复旦大学附属肿瘤医院 | 三阴性乳腺癌免疫治疗疗效预测标志物ccl19的检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6483705B2 (en) * | 2001-03-19 | 2002-11-19 | Harris Corporation | Electronic module including a cooling substrate and related methods |
| AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
| EP3230498B1 (en) * | 2014-12-09 | 2023-01-18 | Merck Sharp & Dohme LLC | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
| WO2016168133A1 (en) * | 2015-04-17 | 2016-10-20 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| CA3010617A1 (en) * | 2016-01-22 | 2017-07-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US11337969B2 (en) * | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
-
2019
- 2019-04-12 JP JP2020555862A patent/JP2021521439A/ja active Pending
- 2019-04-12 CN CN201980025714.9A patent/CN112005114A/zh active Pending
- 2019-04-12 WO PCT/US2019/027169 patent/WO2019200223A1/en not_active Ceased
- 2019-04-12 CA CA3095331A patent/CA3095331A1/en active Pending
- 2019-04-12 US US17/045,697 patent/US20210025895A1/en not_active Abandoned
- 2019-04-12 EP EP19785850.9A patent/EP3775877A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521439A5 (https=) | ||
| JPWO2019200223A5 (https=) | ||
| Mackintosh et al. | Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: a position statement from the Thoracic Society of Australia and New Zealand 2023 revision | |
| Ansari et al. | Pancreatic cancer: yesterday, today and tomorrow | |
| Berkel et al. | Patient’s skeletal muscle radiation attenuation and sarcopenic obesity are associated with postoperative morbidity after neoadjuvant chemoradiation and resection for rectal cancer | |
| Albuquerque et al. | Impact of partial versus whole breast radiation therapy on fatigue, perceived stress, quality of life and natural killer cell activity in women with breast cancer | |
| Jacquinot et al. | A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study | |
| JP2023546357A (ja) | ベネトクラクス－抵抗性急性骨髄性白血病の対象特異的治療 | |
| Tan et al. | Repeated partial splenic artery embolization for hypersplenism improves platelet count | |
| Bu et al. | Inhibition of metastasis of oral squamous cell carcinoma by anti-PLGF treatment | |
| Jensen et al. | Maternal asthma and gestational diabetes mellitus: exploration of potential associations | |
| Rémi et al. | Pharmacological management of bronchorrhea in malignant disease: a systematic literature review | |
| Chen et al. | Complete remission in a patient with sinonasal squamous cell carcinoma receiving neoadjuvant tislelizumab plus chemotherapy: a case report | |
| Xu et al. | Visfatin is negatively associated with coronary artery lesions in subjects with impaired fasting glucose | |
| Wong | Neoadjuvant versus induction chemotherapy: more than semantics | |
| Bragado et al. | Kaposi's Sarcoma in a Steroid-treated Antisynthetase Antibody Syndrome Patient | |
| CN113156123B (zh) | EphA2基因在制备治疗或诊断由细胞焦亡相关蛋白引起的乳腺癌产品中的用途 | |
| Herczeg et al. | Does diabetes affect paraneoplastic thrombocytosis in colorectal cancer? | |
| Patil | Validation of a nomogram for predicting risk of local recurrence for ductal carcinoma in situ | |
| Su et al. | Concurrent aspergillosis and cystic pulmonary metastases in a patient with tongue squamous cell carcinoma | |
| Guo et al. | A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice | |
| Sandborn et al. | Dop53 clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis | |
| Kim et al. | Sarcopenia and hypoxia in patients with obstructive sleep apnea | |
| Janssen et al. | Neoadjuvant folfirinox versus neoadjuvant chemoradiotherapy and adjuvant chemotherapy for resectable and borderline resectable pancreatic cancer: update on the nationwide multicenter preopanc-2 randomized trial | |
| Shitara et al. | MO31-4 Phase 1b/2 trial of tucatinib+ trastuzumab+/-chemotherapy or pembrolizumab in patients with metastatic HER2+ GI cancers |